This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aegerion Pharmaceuticals Inc (AEGR)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 158.37M 48.55M 0.00 0.00
Cost of Sales 12.09M 2.65M 0.00 0.00
Gross Operating Profit 146.29M 45.90M 0.00 0.00
Selling, General, and Administrative Expenses 132.72M 76.08M 34.08M 14.71M
Research & Development 37.98M 29.79M 25.16M 23.69M
Operating Income before D & A (EBITDA) -24.41M -59.97M -59.24M -38.40M
Depreciation & Amortization 2.28M 2.37M 1.23M 407.26K
Interest Income 246.00K 269.00K 162.00K 209.28K
Other Income - Net -2.09M -211.00K -883.00K 747.78K
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -28.55M -62.29M -62.56M -38.76M
Interest Expense 9.94M 722.00K 937.00K 1.11M
Pre-Tax Income -38.49M -63.01M -63.49M -39.88M
Income Taxes 899.00K 347.00K 0.00 0.00
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -39.38M -63.36M -62.27M -39.47M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -39.38M -63.36M -62.27M -39.47M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -39.38M -63.36M -62.27M -39.47M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-39.38M -63.35M -60.90M -38.56M
Preferred Dividends
Net Income Available To Common -39.38M -63.36M -62.27M -39.47M
Basic EPS from Continuing Ops. -1.35 -2.19 -2.64 -2.03
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -1.35 -2.19 -2.64 -2.03
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -1.35 -2.19 -2.64 -2.03
Basic Normalized Net Income/Share -1.35 -2.19 -2.58 -1.99
EPS fr Continuing Ops. -1.35 -2.19 -2.64 -2.03
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -1.35 -2.19 -2.64 -2.03
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -1.35 -2.19 -2.64 -2.03
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-1.35 -2.19 -2.58 -1.99
Dividends Paid per Share 0.00 0.00 0.00 0.00
AEGR News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

AEGR Aegerion Pharmaceuticals Inc

Chart of AEGR

Analysts Ratings for AEGR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 2 2
Moderate Buy 0 0 0 0
Hold 3 3 4 3
Moderate Sell 0 0 0 1
Strong Sell 0 0 0 0
GET AEGR ANALYST REPORT

AEGR Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs